CAMBRIDGE, Mass., Sept. 5, 2018 /PRNewswire/ -- Blueprint
Medicines Corporation (NASDAQ: BPMC), a leader in discovering
and developing targeted kinase medicines for patients with
genomically defined diseases, today announced that company
management will participate in a fireside chat at the
16th Annual Morgan Stanley Global Healthcare Conference
on Wednesday, September 12, 2018 at
1:40 p.m. ET.
A live webcast of the presentation will be available by visiting
the Investors section of Blueprint Medicines' website
at http://ir.blueprintmedicines.com. A replay of the webcast
will be archived on Blueprint Medicines' website for 30
days following the presentation.
About Blueprint Medicines
Blueprint Medicines is developing a new generation of
targeted and potent kinase medicines to improve the lives of
patients with genomically defined diseases. Its approach is rooted
in a deep understanding of the genetic blueprint of cancer and
other disease driven by the abnormal activation of kinases.
Blueprint Medicines is advancing multiple programs in clinical
development for subsets of patients with gastrointestinal stromal
tumors, hepatocellular carcinoma, systemic mastocytosis, non-small
cell lung cancer, medullary thyroid cancer and other advanced solid
tumors, as well as multiple programs in research and preclinical
development. For more information, please
visit www.blueprintmedicines.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-16th-annual-morgan-stanley-global-healthcare-conference-300706667.html
SOURCE Blueprint Medicines